Ensuring a High Quality, Regulatory Compliant, ADC Product

ADC analytical development is at a critical juncture as novel modalities like bispecific ADCs, degrader conjugates, and dual-payload conjugates push innovation while introducing invisible heterogeneity, novel impurities, and biologically confounding potency questions that threaten product understanding and regulatory success.

The 5th ADC Analytical Development Summit is the only technical forum for case study presentations, networking, and deep-dive discussions enabling analytical scientists, whether seasoned ADC veterans or new to the field to advance and troubleshoot strategies together. Over three days, 80+ senior analytical experts, CMC leaders, and quality specialists will examine core challenges spanning early to late-stage development.

With 25+ expert-led case studies from Pfizer, AstraZeneca, Merck, Bristol Myers Squibb, Takeda Pharmaceutical, Sutro Biopharma, Debiopharm, Exelixis, and AbbVie, the summit delivers actionable insight to move beyond average DAR, uncover unknown degradation products, prove dual-target engagement, and manage the transfer of living assays.

Through focused discussions on platform methods for novel conjugates, sterile assay execution, and CMC justifications for novel attributes define the methods and narratives shaping ADC quality.

If you are pushing beyond basic characterization or navigating the case-by-case regulatory frontier for novel ADCs, this is where technical solutions are forged.

Join your peers in Boston to optimize physicochemical, potency, and impurity methods, enable robust DAR assessment, and accelerate submissions for traditional and next-generation ADC products.